198 related articles for article (PubMed ID: 27428741)
1. Influence of geographic origin, sex, and HIV transmission group on the outcome of first-line combined antiretroviral therapy in France.
de Monteynard LA; Matheron S; Gilquin J; Pavie J; de Truchis P; Grabar S; Launay O; Meynard JL; Khuong-Josses MA; Rey D; Simon A; Mahamat A; Dray-Spira R; Costagliola D; Abgrall S;
AIDS; 2016 Sep; 30(14):2235-46. PubMed ID: 27428741
[TBL] [Abstract][Full Text] [Related]
2. Later cART initiation in migrant men from sub-Saharan Africa without advanced HIV disease in France.
de Monteynard LA; Dray-Spira R; de Truchis P; Grabar S; Launay O; Meynard JL; Khuong-Josses MA; Gilquin J; Rey D; Simon A; Pavie J; Mahamat A; Matheron S; Costagliola D; Abgrall S;
PLoS One; 2015; 10(3):e0118492. PubMed ID: 25734445
[TBL] [Abstract][Full Text] [Related]
3. Influence of geographic origin on AIDS and serious non-AIDS morbidity/mortality during cART among heterosexual HIV-infected men and women in France.
de Monteynard LA; Matheron S; Grabar S; de Truchis P; Gilquin J; Pavie J; Launay O; Meynard JL; Khuong-Josses MA; Rey D; Mahamat A; Dray-Spira R; Simon A; Costagliola D; Abgrall S;
PLoS One; 2018; 13(10):e0205385. PubMed ID: 30379870
[TBL] [Abstract][Full Text] [Related]
4. Does region of origin influence the timing and outcome of first-line antiretroviral therapy in France?
Gatey C; Brun A; Hamet G; Diamantis S; Sellier P; Bouchaud O; Garrait V; Rozenbaum W; Molina JM; Abgrall S;
HIV Med; 2019 Feb; 20(2):175-181. PubMed ID: 30506853
[TBL] [Abstract][Full Text] [Related]
5. Sub-Saharan African migrants have slower initial CD4+ cell recovery after combined antiretroviral treatment initiation than French natives.
Seng R; Ghislain M; Girard PM; Cotte L; Meybeck A; Raffi F; Abgrall S; Yazdanpanah Y; Goujard C; Dray-Spira R; Meyer L
AIDS; 2017 Jun; 31(9):1323-1332. PubMed ID: 28492394
[TBL] [Abstract][Full Text] [Related]
6. Timing of combined antiretroviral treatment initiation in male and female migrants living with HIV in Western Europe.
Migrant Health Working Group for the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord
AIDS; 2017 Mar; 31(6):835-846. PubMed ID: 28272136
[TBL] [Abstract][Full Text] [Related]
7. CD4+ cell count recovery after combined antiretroviral therapy in the modern combined antiretroviral therapy era.
Roul H; Mary-Krause M; Ghosn J; Delaugerre C; Pialoux G; Cuzin L; Launay O; Lacombe JM; Menard A; De Truchis P; Delfraissy JF; Weiss L; Costagliola D;
AIDS; 2018 Nov; 32(17):2605-2614. PubMed ID: 30289817
[TBL] [Abstract][Full Text] [Related]
8. Elevated risk of viral rebound on ART in migrants living in France: role of socioeconomic factors.
Abgrall S; Raho-Moussa M; Seng R; Ghislain M; Matheron S; Pialoux G; Goujard C; Meyer L;
Antivir Ther; 2019; 24(7):541-552. PubMed ID: 31868654
[TBL] [Abstract][Full Text] [Related]
9. Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?
Migrant Health Working Group for the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord
HIV Med; 2018 Jan; 19(1):42-48. PubMed ID: 28741837
[TBL] [Abstract][Full Text] [Related]
10. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.
Lapadula G; Cozzi-Lepri A; Marchetti G; Antinori A; Chiodera A; Nicastri E; Parruti G; Galli M; Gori A; Monforte Ad;
AIDS; 2013 Mar; 27(5):769-79. PubMed ID: 23719349
[TBL] [Abstract][Full Text] [Related]
11. The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.
Di Biagio A; Rusconi S; Marzocchetti A; Signori A; Schiavetti I; Bruzzone B; Monno L; Punzi G; Colao MG; Penco G; Zazzi M; De Luca A;
J Med Virol; 2014 Oct; 86(10):1648-55. PubMed ID: 25042976
[TBL] [Abstract][Full Text] [Related]
12. Long-term evolution of CD4+ cell count in patients under combined antiretroviral therapy.
Pantazis N; Papastamopoulos V; Paparizos V; Metallidis S; Adamis G; Antoniadou A; Psichogiou M; Chini M; Sambatakou H; Sipsas NV; Gogos C; Chrysos G; Panagopoulos P; Katsarou O; Gikas A; Touloumi G;
AIDS; 2019 Aug; 33(10):1645-1655. PubMed ID: 31305332
[TBL] [Abstract][Full Text] [Related]
13. Increasing HIV-1 non-B subtype primary infections in patients in France and effect of HIV subtypes on virological and immunological responses to combined antiretroviral therapy.
Chaix ML; Seng R; Frange P; Tran L; Avettand-Fenoël V; Ghosn J; Reynes J; Yazdanpanah Y; Raffi F; Goujard C; Rouzioux C; Meyer L;
Clin Infect Dis; 2013 Mar; 56(6):880-7. PubMed ID: 23223603
[TBL] [Abstract][Full Text] [Related]
14. Long-term response to combination antiretroviral therapy in HIV-infected children in the Netherlands registered from 1996 to 2012.
Cohen S; Smit C; van Rossum AM; Fraaij PL; Wolfs TF; Geelen SP; Schölvinck EH; Warris A; Scherpbier HJ; Pajkrt D;
AIDS; 2013 Oct; 27(16):2567-75. PubMed ID: 23842124
[TBL] [Abstract][Full Text] [Related]
15. Impaired CD4 T-cell count response to combined antiretroviral therapy in antiretroviral-naive HIV-infected patients presenting with tuberculosis as AIDS-defining condition.
Cingolani A; Cozzi Lepri A; Castagna A; Goletti D; De Luca A; Scarpellini P; Fanti I; Antinori A; d'Arminio Monforte A; Girardi E
Clin Infect Dis; 2012 Mar; 54(6):853-61. PubMed ID: 22157323
[TBL] [Abstract][Full Text] [Related]
16. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
[TBL] [Abstract][Full Text] [Related]
17. Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa.
Kroeze S; Ondoa P; Kityo CM; Siwale M; Akanmu S; Wellington M; de Jager M; Ive P; Mandaliya K; Stevens W; Boender TS; de Pundert ME; Sigaloff KCE; Reiss P; Wit FWNM; Rinke de Wit TF; Hamers RL
AIDS; 2018 May; 32(8):1043-1051. PubMed ID: 29547445
[TBL] [Abstract][Full Text] [Related]
18. Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients.
Bouteloup V; Sabin C; Mocroft A; Gras L; Pantazis N; Le Moing V; d'Arminio Monforte A; Mary-Krause M; Roca B; Miro JM; Battegay M; Brockmeyer N; Berenguer J; Morlat P; Obel N; De Wit S; Fätkenheuer G; Zangerle R; Ghosn J; Pérez-Hoyos S; Campbell M; Prins M; Chêne G; Meyer L; Dorrucci M; Torti C; Thiébaut R;
HIV Med; 2017 Jan; 18(1):33-44. PubMed ID: 27625009
[TBL] [Abstract][Full Text] [Related]
19. Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial.
Chéret A; Nembot G; Mélard A; Lascoux C; Slama L; Miailhes P; Yeni P; Abel S; Avettand-Fenoel V; Venet A; Chaix ML; Molina JM; Katlama C; Goujard C; Tamalet C; Raffi F; Lafeuillade A; Reynes J; Ravaux I; Hoën B; Delfraissy JF; Meyer L; Rouzioux C;
Lancet Infect Dis; 2015 Apr; 15(4):387-96. PubMed ID: 25701561
[TBL] [Abstract][Full Text] [Related]
20. Disparities in Initiation of Combination Antiretroviral Treatment and in Virologic Suppression Among Patients in the HIV Outpatient Study, 2000-2013.
Novak RM; Hart RL; Chmiel JS; Brooks JT; Buchacz K;
J Acquir Immune Defic Syndr; 2015 Sep; 70(1):23-32. PubMed ID: 25886926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
